EGFR and lung cancer: EGFR exon 20 insertions (EGFR e20ins) were highly diversified in terms of insertion patterns and co‐occurring mutations, and these EGFR e20ins variants showed different clinical responses to various EGFR tyrosine kinase inhibitors (TKIs) in lung cancer, suggesting the clinical importance of selecting proper EGFR TKI treatment based on the specific EGFR e20ins type.